RxDoctor Payments Data

Thomas Aiello, MD

Ophthalmology · Brooklyn, NYNPI 1366444754

Payments from drug & device makers

$3,336in general payments, 2019–2025

Across 109 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$560
  • Bausch & Lomb Americas Inc.$338
  • Oyster Point Pharma, Inc.$256
  • Glaukos Corporation$252
  • Tarsus Pharmaceuticals, Inc.$216
  • Kala Pharmaceuticals, Inc.$216
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,336 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$374,737
Medicare patients
742
Services billed
3,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$65,154
LumiganBimatoprost102$34,545
ProlensaBromfenac Sodium62$21,304
Lotemax SmLoteprednol Etabonate66$17,329
VyzultaLatanoprostene Bunod51$16,443
RocklatanNetarsudil Mesylat/Latanoprost31$12,653
Bromfenac Sodium43$7,541
Prednisolone Acetate154$5,847
Cyclosporine13$5,769
BesivanceBesifloxacin Hcl24$5,335
IlevroNepafenac13$4,655
Dorzolamide-TimololDorzolamide/Timolol/Pf21$4,580
MoxifloxacinMoxifloxacin Hcl166$3,841
Loteprednol Etabonate22$2,873
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat117$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance, Loteprednol Etabonate$126$46,841174 claims
Bausch & Lomb Americas Inc.Vyzulta$338$16,44351 claims
Aerie Pharmaceuticals, Inc.Rocklatan$21$12,65331 claims
NovartisIlevro$174$4,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →